<DOC>
	<DOCNO>NCT01229813</DOCNO>
	<brief_summary>Patients metastatic colorectal cancer treat chemotherapy accord investigator choice . In addition chemotherapy treatment , treatment bevacizumab give concomitantly . This treatment continue 18 week . Meanwhile , patient KRAS status test . After fulfil 18 week induction treatment , patient respond ( complete response/partial response versus stable disease ) randomize maintenance treatment . Patients KRAS WT randomize either bevacizumab alone , bevacizumab erlotinib . Patient KRAS mutation randomize either bevacizumab , metronomic capecitabine . Translational research perform , purpose find predictive factor blood tumor tissue .</brief_summary>
	<brief_title>Avastin Chemotherapy Followed KRAS Stratified Randomization Maintenance Treatment First Line Treatment Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Untreated metastatic colorectal carcinoma Age 18 yr Measurable disease accord Response Evaluation Criteria solid Tumors ( RECIST criterion ) ECOG performance status 0 1 Life expectancy 3 month Adequate haematological , renal liver function Tumor tissue available determination KRAS mutational status Blood sample paraffin embed tumor tissue translational research Adjuvant therapy within 6 month CNS metastases Clinically significant atherosclerotic vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Untreated</keyword>
	<keyword>First line</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Maintenance treatment</keyword>
	<keyword>KRAS wt</keyword>
	<keyword>KRAS mutate</keyword>
	<keyword>Anti-angiogenetic treatment</keyword>
	<keyword>Metronomic capecitabine</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>erlotinib</keyword>
	<keyword>Translational research</keyword>
</DOC>